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Summary As of June 1998, four randomized trials have been completed comparing the combination of paclitaxel and cisplatin with a
cisplatin-based control arm. The results of three of these trials are available; one has been published as a full paper, the other two in abstract
form only. Two of the reported trials (GOG-111 and the Intergroup trial) provide clear evidence thatcisplatin combined with paclitaxel is a more
effective regimen than one using the same dose of cisplatin combined with cyclophosphamide. The results of the third reported trial (GOG-
132) are rather different, suggesting that a higher dose of single-agent cisplatin may be as effective as the paclitaxel/cisplatin combination
tested in the other two trials. A number of explanations for these unexpected results have been proposed: false-positive results in GOG-111
and the Intergroup trial; false-negative results in GOG-132; high crossover in GOG-132 (including crossover before progression); the
cyclophosphamide in the control arm of GOG-111 and the Intergroup trial had a negative impact on outcome in the control group in these
trials; the higher dose of cisplatin when used as a single agent in GOG-132 had a positive impact on outcome forthe control group in this trial.
These explanations are discussed in detail, and their implications explored.
Keywords: paclitaxel; cisplatin; ovarian cancer; randomized trials
As of June 1998, four randomized trials have been completed
comparing the combination of paclitaxel and cisplatin with a
cisplatin-based control arm (Table 1).
The results of these trials, in terms of progression-free and
overall survival, are presented in Figure 1, summarized in the
manner of a meta-analysis. The results of one trial (GOG-114) are
not yet available and there is considerable statistical and clinical
heterogeneity in the other three trials, and so the results have not
been formally combined. It should be noted that the Intergroup and
GOG-132 trials have been reported in abstract form only at meet-
ings of the American Society of Clinical Oncology (ASCO); the
information contained in the figure is based exclusively on the
published information available for these trials, and is therefore
only approximate. The methods used to estimate the relevant
statistics, when these are not explicitly stated in the publications,
are outlined in the appendix.
The very positive results of the first trial, GOG-111, were first
presented in 1993, updated in 1995 and published in full in 1996
(McGuire et al, 1993, 1995a, 1996). These results excited consid-
erable interest in the paclitaxel/cisplatin combination and the
results ofthe confirmatory Intergroup trial, which was very similar
in design, were eagerly awaited. The preliminary results of this
trial, first presented in 1997, and the update, which was presented
a year later, provide a clear confirmation ofthe results from GOG-
111 (Piccart et al, 1997; Stuart et al, 1998). Both trials report very
similar estimated improvements in progression-free and overall
survival and, importantly, the Intergroup trial replicated the
unusual observation that the improvement in overall survival
appears to be as large as that in progression-free survival (Parmar
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and Sandercock, 1996). This latter effect is seen clearly in both
trials despite the fact that GOG-111 reported little crossover to
paclitaxel on relapse (McGuire et al, 1996), whereas in the
Intergroup trial a sizeable proportion of the control group were
reported as having received some paclitaxel-containing treatment
later on (Piccart M.J., personal communication); the crossover on
progression in the Intergroup trial does not appear to have
markedly diluted the overall survival difference between the arms.
The results of the cyclophosphamide/cisplatin (CP) vs pacli-
taxel/cisplatin (TP) comparison in the third trial, GOG-114, are
not yet available; the CP control arm ofthis trial was closed early
(in September 1993) when the first results from GOG-Ill became
available. The results from the two arms which remained open to
accrual were presented at ASCO in 1998 (Markman et al, 1998),
but the results from the relatively small number ofpatients on the
original control arm are not yet available. The results from the
fourth trial listed above, GOG-132 (which included a third arm of
single-agent paclitaxel), were first presented in 1997 at the same
meeting as the preliminary results of the Intergroup trial
(Muggia et al, 1997). The results of this trial are quite different
from the results of GOG-111 and the Intergroup trial; possible
explanations for this difference will be considered in more detail
below.
The considerable neurotoxicity of the paclitaxel/cisplatin
combination, noted in GOG-1 11 and later confirmed by the
Intergroup trial and GOG-132, has led to some interest in the use
of carboplatin in place of cisplatin in this combination. In fact,
since 1995, paclitaxel/carboplatin has increasingly been used,
despite a lack of evidence from randomized trials investigating
this combination (McGuire et al, 1996). Only one trial (ICON3)
has been conducted comparing the paclitaxel/carboplatin combi-
nation directly with a standard platinum-based control arm; it is
anticipated that the first results of this trial will be available early
in 1999. Two trials (with 190 and 798 patients respectively)
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Table 1 Trials comparing paclitaxel/cisplatin with a cisplatin-based control arm
Trial Comparison (doses in mg m-2) Patient group Accrual and accrual dates Results available
GOG-111 Paclitaxel (135, 24-h infusion) FIGO stage IlIl or IV 410 May 1993 (abstract)
and cisplatin (75) with suboptimal May 1995 (abstract)
vs residual disease April 1990-March 1992 January 1996 (paper)
Cyclophosphamide (750) (McGuire et al, 1993,
and cisplatin (75) 1995a, 1996)
Intergroup Paclitaxel (175, 3-h infusion) FIGO stage IIB-C, III 680 May 1997 (abstract)
(EORTC and cisplatin (75) or IV with optimal May 1998 (abstract)
NCIC vs or suboptimal April 1994-August 1995
NOCOVA Cyclophosphamide (750) residual disease (Piccart et al, 1997;
Scottish) and cisplatin (75) Stuart et al, 1998)
GOG-114 Paclitaxel (135, 24-h infusion) Optimal residual Approximately 140
and cisplatin (75) disease [in this comparison (CP arm
vs closed early with 66
Cyclophosphamide (750) patients); 589 in three arms] Results of this
and cisplatin (75) March 1992-April 1995 comparison not yet
(CP arm closed September 1993) available
GOG-132 Paclitaxel (135, 24-h infusion) FIGO stage IlIl or IV 424 May 1997 (abstract)
and cisplatin (75) with suboptimal (in this comparison; 648 in three
vs residual disease arms)
Cisplatin (100) March 1992-May 1994 (Muggia et al, 1997)
have compared paclitaxel/cisplatin with paclitaxeVcarboplatin.
Preliminary results ofboth trials were reported at the 1997 ASCO
meeting, and the results ofthe larger trial were updated at the same
meeting in 1998 (Neijt et al, 1997; du Bois et al, 1997, 1998). Both
trials have found less toxicity, particularly neurotoxicity, with
paclitaxel/carboplatin and to date neither trial suggests any differ-
ence in effectiveness between the two regimens, although the data
on progression-free and overall survival from these trials are still
relatively immature.
With two extremely positive trials in favour of
paclitaxel/cisplatin showing such consistency in outcome, and
some evidence to suggest that paclitaxel/carboplatin may be
similarly effective with less toxicity, it is tempting to conclude
that either cisplatin or carboplatin in combination with pacli-
taxel significantly improves outcome when compared with other
platinum-based treatments. However, the results of the fourth
trial, GOG-132, comparing the paclitaxel/cisplatin combination
with, in this case, single-agent cisplatin diverge considerably
from the other two reported trials, and the reasons for this diver-
gence need to be examined and understood. In a presentation at
ASCO in 1996 Muggia and colleagues suggested five possible
explanations to account for these unexpected results:
* false-positive results in GOG-111 and the Intergroup trial;
* false-negative results in GOG-132;
* high crossover in GOG-132 (including crossover before
progression);
* the cyclophosphamide in the control arm ofGOG- 111 and the
Intergroup trial had a negative impact on outcome for the
control groups in these trials;
* the higher dose ofcisplatin when used as a single agent in
GOG-132 had a positive impact on outcome for the cisplatin
control group in this trial.
What about GOG-132? The statistical explanations
False-positive results in GOG-111 and the Intergroup trial
Did the difference between the two arms in the Intergroup trial and
GOG-111 arise purely by chance? The results of both of these
trials are highly significant for both progression-free and overall
survival, and the results ofboth trials are very similar. It is clearly
extremely unlikely that both of these sets of observations could
have arisen by chance alone.
False-negative results in GOG-132
Did the results of GOG-132 arise purely by chance? Although the
differences between single-agent cisplatin and the paclitaxel/
cisplatin combination were not statistically significant, the esti-
mated difference in median progression-free survival was 2.3
months and in median survival was 3.6 months, both in favour of
the single-agent cisplatin arm. The (approximate) 95% confidence
intervals around the hazard ratios for P vs TP in GOG-132 do not
overlap with those for the CP vs TP comparisons in GOG- 111 and
the Intergroup trial, and even the 99% confidence intervals barely
coincide. The X2 test for heterogeneity in these results (summa-
rized in Figure 1) indicates rather more between-trial variability
than can reasonably be ascribed to chance (Parmar et al, 1996). If
GOG-111 and the Intergroup trial results are reliable estimates of
the true (underlying) difference between the arms in GOG-132, it
is, again, extremely unlikely that the outcomes seen in GOG-132
could have arisen by chance alone.
What about GOG-132? The crossover explanation
Althoughinformation onsalvagetherapy was notoriginally collected
during the course of this trial, this information was collected retro-
spectively. The extent and timing of crossover has added somewhat
to the difficulty in interpreting the results ofthe trial.
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Figure 1 Progression-free survival and overall survival results to date (based on published data only). The hazard ratios (HR) with 95% and
99% Cls are plotted and associated statistics (approximated from the published information to date, see appendix) in each of the trials are
presented. The number of events and total number of patients in each comparison are given, when these figures have been published. The O-E
statistic indicates the difference between the observed and expected number of events on the paclitaxel/cisplatin arms (negative values indicate
that patients on this group did better than controls, positive values that the controls did better). The Vstatistic is the reciprocal of the variance of
ln[HR] and indicates the amount of information contributed by each trial. The sizes of the boxes representing the estimated HR in the plots are
directly proportional to V(the Vapproximated here for progression-free survival in the Intergroup trial is probably rather high; see appendix). Note
that the hazard ratio is not symmetrically distributed; for example, a hazard ratio of 0.5 in favour of the treatment arm is equivalent in magnitude
to a hazard ratio of 2.0 in favour of control. The chi-squared statistics given for each comparison relate to the (between trial) heterogeneity of the
results
High crossover in GOG-132 (including crossover before
progression)
It has been noted that around half of the patients in GOG-132
crossed over to one of the other treatment groups, with some
crossing over before they progressed (Gore et al, 1997). At this
time, there is little published information on the second-line treat-
ments used in GOG-132, but at the 1997 ASCO meeting it was
reported that around 50% of patients on each of the three arms
received some sort of treatment before progression. A variety of
treatments were used before progression on each of the arms.
The most common 'pre-emptive' treatment on the single-agent
cisplatin arm was paclitaxel. The platinum agents were more
commonly used 'pre-emptively' on the single-agent paclitaxel
arm. A wider variety of treatments, most commonly paclitaxel-
and/or platinum-containing regimens, were used before progres-
sion for those initially receiving the combination treatment.
It has, therefore, been suggested that this trial was essentially a
comparison of sequential cisplatin/paclitaxel vs sequential
paclitaxel/cisplatin vs paclitaxel/cisplatin combined, and that this
accounts for the failure to detect the sorts of differences which
might have been expected on the basis of the Intergroup trial and
GOG-111 (Gore et al, 1997). There are a number ofpoints to note
about this suggestion.
Firstly, the survival benefit of paclitaxel as a second-line treat-
ment (after progression) has never been demonstrated. The only
reported randomized trial ofpaclitaxel in relapsed disease compared
single-agent paclitaxel against CAP (cyclophosphamide, doxoru-
bicin and cisplatin) in platinum-sensitive relapsed ovarian cancer
(Colombo et al, 1996). The trial was stopped early because ofa large
benefit emerging in favour of CAP. Two ongoing European trials,
ICON4 and an AGO Study Group trial, are currently addressing the
question of whether paclitaxel combined with platinum may be of
benefit in these patients (with platinum-sensitive relapsed disease)
when compared with standard platinum rechallenge. It is also worth
noting that the survival results from the Intergroup trial are very
similar to those of GOG-111 despite the report that a sizeable
proportion of the control group received paclitaxel on progression
(Piccart et al, 1997), although GOG-111 reported very little
crossover to paclitaxel (McGuire et al, 1996), suggesting that the
second-line use of the drug in the Intergroup trial may have had
limited impact on overall survival.
These observations, and the fact that the progression-free and
overall survival results in GOG-132 are similar (to each other) in
both magnitude and direction, would seem to indicate that, if
crossover to paclitaxel does account for the anomalous results of
this trial, it is the early crossover, treatment with paclitaxel before
progression, that is likely to be responsible. That is, the effect of
the early crossover on the cisplatin control arm was enough to
completely eliminate the benefit of paclitaxel/cisplatin that would
be anticipated from the Intergroup trial and GOG- 111.
It is important to remember here that only around half of the
single-agent cisplatin group are reported to have received any kind
of 'pre-emptive' treatment, and not all ofthese received paclitaxel
at this point (i.e. before progression). According to the crossover
theory, the benefit (of paclitaxel) to these patients was enough to
improve outcome sufficiently that the single-agent cisplatin group
as a whole (including the large number of patients who did not
receive paclitaxel before progression) did at least as well, and
possibly better, than the group in which all ofthe patients received
paclitaxel/cisplatin initially. This is a quite remarkable observa-
tion, particularly when it is remembered that around half of the
group initially treated with paclitaxel/cisplatin also received addi-
tional treatment (of various kinds) before they progressed. If the
crossover explanation is sufficient to explain the results of this
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trial, then two important questions arise regarding the way pacli-
taxel might best be used in the treatment of this disease.
(1) Does paclitaxel benefit only certain groups of patients, and
the group on the single-agent cisplatin arm in GOG-132 who
received paclitaxel early happened to include those patients who
would benefit the most? The major reason for 'pre-emptive' treat-
ment in GOG- 132 was reported as persistent disease after first-line
treatment, and so it is possible that these patients were somewhat
different as a group from those who were not retreated until
progression occurred. The remarkable results for the single-agent
cisplatin arm as a whole are thus, perhaps, suggestive of a poten-
tially important difference between subgroups of patients with
respect to the degree of benefit which might be derived from pacli-
taxel. The results, when they become available, of the ongoing
trials comparing the paclitaxel/platinum combination with stan-
dard platinum rechallenge in platinum-sensitive relapsed disease
may provide some useful evidence in this context.
It is worth emphasizing here that because the 'semi-sequential'
treatment plan in GOG- 132 simply happened, rather than being
specified by the protocol, interpretation of the results is really very
difficult. The question raised here, as to whether there may be
substantial differences in effect in subgroups of patients, has some
relevance to this point. The rationale for the 'subgroup explana-
tion' is that those patients who received paclitaxel after initial
treatment with single-agent cisplatin were largely selected by their
poor response to cisplatin. Those patients on the single-agent
paclitaxel arm who received cisplatin before progression were
similarly selected, but in this case the selection factor was, in the
main, their poor response to paclitaxel. A poor response to the
combination of the two agents was the major reason for further
treatment in the paclitaxel/cisplatin arm. Thus, although the three
subgroups which received additional treatment before progression
in this trial were similar in size, they may be substantially different
from each other, making interpretation of the overall outcomes for
the groups particularly difficult (with or without the contradictory
results from other trials).
(2) Does sequential treatment have a greater effect than the two
drugs given concurrently? Some sort of sequential or carryover
effect could also account for the apparently disproportionate
benefit of 'pre-emptive' paclitaxel in the single-agent cisplatin
arm of GOG-132. There is no need here, necessarily, to postulate
some sort of 'pump-priming' biological effect. Any additional
benefit of sequential treatment, if there is additional benefit, could
simply result from the ability to administer higher doses of these
drugs as single agents compared with combination treatment; the
question of platinum dose has already been raised, and is
discussed in more detail below.
The third arm of this trial (single-agent paclitaxel, with a
proportion receiving platinum before progression) was signifi-
cantly worse in terms of progression-free survival than both the
single-agent cisplatin and the paclitaxel/cisplatin arms. The signif-
icant differences in response rates between the arms (46% on T
compared with 74% on P and 72% on TP), and in the proportions
progressing before six cycles of the allocated treatment had been
given (19% on T compared with 7% on P and 6% on TP), suggest
that platinum is the more active agent (Muggia et al, 1997).
Although interpretation of later outcomes is complicated by
crossover, the possible subgroup effects noted earlier, and the
possibility of an order-dependent sequential effect, the difference
in progression-free survival between single-agent paclitaxel and
the two cisplatin-containing arms is, thus, likely to be because of
the fact that many patients on the single-agent paclitaxel arm were
denied platinum early on.
What about GOG-132? The control arm explanations
The Intergroup trial and GOG-1 11 demonstrate convincingly that
combining cisplatin with paclitaxel is considerably more effective
than combining it with cyclophosphamide. One explanation for
the results of GOG-132 is that a higher dose of cisplatin, given as
a single agent, is similarly effective. Could cyclosphosphamide be
detrimental in combination with platinum and/or does the dose of
platinum matter?
Cyclophosphamide in the control arm of the Intergroup trial
and GOG-111 had a negative impact on outcome in the
control groups in these trials
The platinum drugs are acknowledged to be the single most effec-
tive agents in this disease. Cyclophosphamide and cisplatin have a
similar mode of action, and give rise to the same mechanisms
of drug resistance (Kirkwood et al, 1994). Is it possible that
cyclophosphamide confers increased resistance to cisplatin
without being effective enough itself to counteract this effect?
There is little direct evidence to support (or deny) this suggestion
because there are few trials which have, intentionally or uninten-
tionally, attempted to isolate the effect of cyclosphosphamide
when given in combination with cisplatin.
Although there is a biological rationale for the 'cyclophos-
phamide explanation', it could also be suggested that the alkyl-
ating agents are simply less effective than platinum and that their
main contribution is, thus, to the toxicity of the regimen, making
treatment harder to give on time and at full planned doses. In
GOG-111, the CP regimen was reported as being somewhat harder
to administer at planned doses than the TP regimen (McGuire et
al, 1996), and the potential influence of this factor on the overall
outcome in this trial has been commented on (Lacave et al, 1996).
Whatever the role of cyclophosphamide in this story, there is
certainly some evidence to suggest that CP may not be the most
effective platinum-based treatment. A number of trials were
conducted during the 1980s to investigate whether the addition of
doxorubicin (A) to CP was beneficial. A meta-analysis ofthe CAP
vs CP trials (based on individual patient data), which was first
published in 1991 and included a total of 1194 patients from four
trials, showed a significant benefit to CAP, with an estimated
hazard ratio for overall survival of 0.85 and a 95% confidence
interval around this estimate of 0.75-0.98 (Ovarian Cancer Meta-
analysis Project, 1991). A recent update of this meta-analysis
confirms these results (M. Buyse, personal communication). Two
further meta-analyses (based on summary data from the literature),
examining CAP vs CP and a wider range of anthracycline-
containing regimens respectively, drew similar conclusions
(Fanning et al, 1992; A'Hern and Gore, 1995).
The higher dose ofcisplatin when used as a single agent in
GOG-132 had a positive impact on outcome for the
cisplatin control group
Few large randomized trials have directly addressed the question
of dose and/or dose intensity in ovarian cancer, and three meta-
analyses have been conducted in an attempt to address the issue
(Levin and Hryniuk, 1987; Levin et al, 1993; Torri et al, 1993).
These meta-analyses used somewhat different methodologies, but
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drew similar conclusions in favour of higher doses of platinum.
However, they were all based on (somewhat incomplete) summary
data from the published literature, which may have introduced
publication bias. Furthermore, they were largely based on trials
published before 1990; the range of platinum doses regarded as
'high' and 'low' are rather different now compared with the 1970s
and early 1980s, when most of these trials were designed and
conducted, and so the conclusions from these meta-analyses may
be strongly influenced by trial comparisons which have little or no
relevance today.
One of the problems in trying to synthesize the results of those
trials which have addressed this question (directly or indirectly) is
in separating the issue of total dose and dose intensity. Another
problem is how to separate the issue ofoverall dose (or dose inten-
sity) ofall drugs given and specifically the dose (or dose intensity)
of platinum, or indeed that of any individual agent used in
combination regimens. To illustrate this problem, it may be
instructive here to look at the results of two of the larger trials
conducted in this area, both comparing standard with high-dose
CP regimens.
The first trial, GOG-97 (McGuire et al, 1995b), randomized a
total of 485 patients and compared eight cycles of cyclophos-
phamide (500 mg m-2) and cisplatin (50 mg m-2) with four cycles
of cyclophosphamide (1000 mg m-2) and cisplatin (100 mg m-2).
Median progression-free survival was 12.1 months, compared
with 14.3 months on the more intense regimen; median overall
survival was 19.5 months compared with 21.3 months. These
differences were not statistically significant; the estimated hazard
ratio for overall survival was 0.96 with a 95% confidence interval
around this estimate of0.81-1.13).
The second trial, conducted by the Scottish Group (Kaye et al,
1992, 1996), was stopped early on ethical grounds, with just 191
patients randomized. The trial compared cyclophosphamide
(750 mg m-2) and cisplatin (50 mg m-2) with cyclophosphamide
(750 mg m-2) and cisplatin (100 mg m-2), with both regimens
given 3 weekly for six cycles. The second report ofthis trial, based
on more mature data (Kaye et al, 1996), reports a median progres-
sion-free survival of approximately 9 months on the lower dose
regimen compared with 18 months on the higher dose regimen;
median overall survival was around 16 months compared with 28
months. The hazard ratio for progression-free survival is not
reported in the paper; based on the median progression-free
survival on each arm (estimated from the published progression-
free survival curves using the method outlined by Pamal et al,
1998), the hazard ratio is approximately 0.66. The statistics for
overall survival have been published; these differences were (just)
significant at the 5% level (P = 0.043), with an estimated hazard
ratio for overall survival of 0.68 and a 95% confidence interval
around this estimate of0.46-0.99.
These differences in outcome between two apparently quite
similar trials could, of course, have arisen by chance, or be due to
differences in thepatient groups recruited to the trials, but there are
two important differences in the designs used which should not be
overlooked and which illustrate the essential difficulty of drawing
firm conclusions from the results of those few trials which have
directly addressed the issue of dose and dose intensity in ovarian
cancer.
Firstly, GOG-97 doubled the dose intensity (of both drugs) but
kept the total dose the same by giving only half as many cycles of
the higher dose regimen, whereas the Scottish Group trial doubled
both the dose intensity and the total dose (of cisplatin) by giving
the same number of cycles on both arms. Secondly, as already
alluded to, GOG-97 doubled the dose intensity of both cisplatin
and cyclophosphamide in the high dose arm, whereas the Scottish
Group trial kept the dose of cyclophosphamide the same in
both arms.
We are, thus, left uncertain as to why these trials differed in
outcome (if not by chance alone). The higher total dose, rather
than the dose intensity, of cisplatin given may have contributed to
the difference seen in the Scottish Group trial, as this factor did not
differ between the two arms in GOG-97. However, as discussed
above, doubts have recently been raised as to the role of
cyclophosphamide in this combination. Could a potential benefit
of higher cisplatin dose intensity in the GOG trial have been
obscured by a negative impact from the higher dose intensity of
cyclophosphamide, which was not dose intensified in the Scottish
Group trial?
There are a number ofother trials which could help to shed light
on this issue, having used a similar design to the GOG trial (e.g.
Colombo et al, 1993), or to the Scottish Group trial, using cisplatin
(e.g. Conte et al, 1996) or carboplatin (e.g. Jakobsen et al, 1997).
However, it is inadvisable to comment on the results of the trials
referenced here without systematically identifying other trials
(published and unpublished) which have used similar designs.
These are not questions which can be reliably answered without a
careful systematic evaluation of all the evidence, perhaps through
meta-analysis.
After the results ofGOG-97 and the Scottish Group trial, the CP
regimen using 750 mg m-2 cyclophosphamide and 75 mg m-2
cisplatin 3 weekly for six cycles has been widely adopted as a
clinical compromise between the suggestion ofimproved outcome
with the higher dose regimen and the cost of increased toxicity
(Kaye et al, 1996). This may be a reasonable compromise, but
because few trials have compared regimens using 75 mg m-2
cisplatin with regimens using either 50 or 100 mg m-2 statements
regarding the relative effectiveness of this regimen are based
on the assumption of an approximately linear dose-outcome
relationship in the range 50-100 mg m-2cisplatin.
So why is GOG-132 different?
Although a number ofplausible explanations have been offered as
to why the results of GOG-132 are so different from those of the
Intergroup trial and GOG- 111, and indeed each of them may have
had some part to play, there is currently little direct evidence to
help determine how much influence each of these factors may
have had.
None of the explanations proposed are, on their own, fully
supported by or consistent with the available evidence, and some
are barely tenable unless we assume that there are additional
underlying and as yet unknown processes at work. If one were to
conclude, from GOG-111 and the intergroup trial, that paclitaxel
does provide an important step forward in the first-line treatment
ofthis disease, then GOG-132 suggests that combination treatment
initially for all patients may not be the optimum way to use the
drug. If, however, GOG-132 led one to conclude that paclitaxel is
not of any great importance in the first-line treatment of this
disease, then the results of GOG-111 and the intergroup trial
suggest we have not progressed as far as we might have thought in
our understanding of the platinum agents in this disease. We
conclude that there is much about both paclitaxel and the platinum
agents that is not yet well understood.
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When will we know more?
More information about crossover and the treatment comparisons
in GOG-132 and the Intergroup trial will become available when
the full papers for these trials are published (Muggia et al, 1998),
and the results of the CP vs TP comparison in GOG-1 14 may also
be informative despite the small numbers in this comparison. The
results (when available) of the two ongoing trials, ICON4 and the
AGO Study Group trial which are comparing paclitaxel/platinum
combinations with standard platinum rechallenge in platinum-
sensitive relapsed disease, may give valuable insight into the
subgroup question posed earlier, and there is also some ongoing
work examining molecular characteristics of the disease which
may influence response to different treatments. The mature results
of the paclitaxel/cisplatin vs paclitaxel/carboplatin trials, along
with the results of the ICON3 trial which compared either CAP or
single-agent carboplatin with the paclitaxel/carboplatin combina-
tion, may further help to resolve at least some of the issues
discussed here. ICON3 will provide the first direct comparison of
the paclitaxel/carboplatin combination with a platinum-based
control and also a (to some extent confirmatory) comparison of a
paclitaxel/platinum combination with two control treatments
which have been shown to be equivalent to each other (Torri,
1996; ICON collaborators, 1998), and which may be more effec-
tive than CP as used in the Intergroup trial and GOG-111. Those
patients selecting single-agent carboplatin (with doses calculated
by the 'area under the concentration-time curve' (AUC) method
ofCalvert et al, 1989) as the preferred control treatment in ICON3
are effectively randomized to receive carboplatin AUC5 ± pacli-
taxel, so the trial will also be the first to investigate the 'pure' addi-
tion of paclitaxel to platinum, i.e. without reducing the platinum
dose (as in GOG-132) or replacing another agent with paclitaxel
(as in the Intergroup trial and GOG- I l1). ICON3 completed
accrual in May 1998, with 2039 patients randomized. The first
results are anticipated early in 1999.
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APPENDIX
The information presented in Figure 1 is based on the most up-to-
date published results for each ofthe trials. The amount ofrelevant
statistical information presented in abstracts, and even in full
papers, is not always sufficient to construct these plots directly, but
there are some simple relationships between quantities that allow
reasonably accurate estimation ofthe underlying statistics (Parmar
et al, 1998). The methods used, where necessary, to approximate
these statistics from the published data are outlined below. These
methods are explained in greater detail in Parmar et al (1998).
GOG-111 (McGuire et al, 1996)
The paper gives the hazard ratio (HR) and the 95% confidence
intervals (CIs) for both progression-free and overall survival, the
median progression-free and overall survival on each arm and the
number of events in each comparison. To construct a 99% CI for
HR, an estimate of the standard error (the square root of the vari-
ance) of ln(HR) is required. The 95% CIs in the GOG-11 paper
are given as (0.5-0.8) for both progression-free and overall
survival, around an estimated HR of 0.7 for progression-free
survival and 0.6 for overall survival. Because these figures have
been rounded to one decimal place, an estimate of the standard
error based on the width of the 95% CIs would not be particularly
accurate, and thus the 99% confidence intervals constructed using
this estimate would not be reliable. More accurate approximations
of HR and the variance of ln(HR) may be obtained using alterna-
tive methods, but the authors of the GOG-111 paper have kindly
supplied us with the hazard ratios and the associated 95% and 99%
confidence intervals to two decimal places and these statistics have
been used in Figure 1. The other statistics summarized in Figure 1
are O-E and V; these have been approximated from the hazard
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ratios and 95% confidence intervals (supplied by the GOG
Statistical Office) as follows:
The 95% CI for HR is constructed using the equation
exp(ln(HR)± 1.96fIV) and so V= (2 x 1.96/1n(uppC) -
In(lowCI)2, where uppCI and lowCI are the upper and lower
extremes of the 95% confidence interval; V is a measure of the
amount ofinformation available from the trial and is the reciprocal
of the variance of the log hazard ratio (i.e. se(ln[HR]) = l\INV).
There are two direct methods of calculating HR for survival
comparisons, HR = (Or-Er) and HR = exp(Q75r) where 0 is the
observed number ofevents (in control and research groups respec-
tively) and E the expected number of events calculated by the
logrank method. The two methods usually give very similar values
in practice. The expected number ofevents (E) are not given in the
paper, but with an estimate of V and HR the O-E statistic may be
approximated by (°r - Er) = ln[HR] x V.
The estimated statistics for GOG-1Il are thus:
End point Progression-free Overall survival
survival
HR (published) 0.7 0.6
Medians (published) 13 vs 18 24 vs 38
HR (to 2 dp) 0.66 0.61
Events (n) (published) 313 (174 + 139) 235 (137 + 98)
V(estimated) 76.38 56.98
O-E (estimated) -31.74 -28.17
The confidence intervals for the hazard ratios (kindly supplied by
the GOG Statistical Office) are:
Progression-free Overall survival
survival
95% Confidence interval (0.53-0.83) (0.47-0.79)
99% Confidence interval (0.49-0.89) (0.43-0.86)
Intergroup trial (Stuart et al, 1998)
No hazard ratios are given in the published abstract; the median
progression-free and overall survival for each arm and the number
of deaths are given. The progression-free survival results given in
this abstract are those presented (but not published) a year earlier.
The hazard ratios may be approximated by the ratio of median
survival times (i.e. MIlM). The standard error for HR for overall
survival in this trial may be approximated from the number of
deaths because se(ln[HR]) = W' and V= n/4 where n is the number
ofdeaths (events). These approximations of (HR and V) combined
with the methods outlined previously may be used to calculate the
relevant statistics from the published information relating to
overall survival in this trial. The statistics for progression-free
survival are a little more difficult, as the number of events has not
been published. However, the P-value for the progression-free
survival comparison is given as P=0.0001. This P-value relates to
the X2 distribution with one degree offreedom, giving a X2 value of
approximately 15. The %2 statistic may be calculated using either
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the logrank or the Mantel-Haenszel methods, but in practice the
two usually produce very similar values. The Mantel-Haenszel X2
statistic is XM (Or -Er)2 statistic is XIM H=-v7-, and because we also have the relation-
ship HR = exp (v0E)I estimates of O-E and V may be obtained
using the approximate value ofX2M H and estimating HR by Mc/Mr.
The estimate obtained here for V using this method is rather high
(because it suggests rather more events than patients), and this
implies that the approximate HR of 0.75 (Mc/Mr) for progression-
free survival may be slightly higher than the true HR for progres-
sion-free survival in this trial. The rather large value of V will
somewhat underestimate the width ofthe confidence intervals (for
any given central estimate), but, overall, the approximate confi-
dence intervals based on these figures should not be far from those
derived directly from the trial data. The estimated statistics for the
Intergroup trial are thus:
End point Progression-free Overall survival
survival
HR (published)
Medians (published) 12 vs 16 25 vs 35
HR (estimated) 0.75 0.71
Events (n) (published) - 299 (168 + 131)
V(estimated) 181.24 74.75
O-E(estimated) -52.14 -25.60
The confidence intervals for the hazard ratios, approximated from
these statistics, are:
Progression-free survival Overall survival
95% Confidence interval (0.65-0.87) (0.57-0.89)
99% Confidence interval (0.62-0.91) (0.53-0.96)
GOG-114
No results from this comparison within COG-114 are available.
GOG-132 (Muggia et al, 1997)
No hazard ratios are given in the published abstract; the median
progression-free and overall survival for each arm and the total
number ofevents (in all three arms) are given. A simple approx-
imation ofthe number ofevents in the two arms under consider-
ation here is 0.67 times the total number of events in all three
arms.
The estimated statistics for GOG-132 are thus:
End point Progression-free Overall survival
survival
HR (published) - -
Medians (published) 16.4 vs 14.1 30.2 vs 26.6
HR (estimated) 1.16 1.14
Events (n) (published) 351 (0.67 x 524) 273 (0.67x408)
V(estimated) 87.75 68.25
O-E(estimated) 13.02 8.94
The confidence intervals for the hazard ratios, approximated from
these statistics, are:
Progression-free survival Overall survival
95% Confidence interval (0.94-1.43) (0.90-1.47)
99% Confidence interval (0.88-1.53) (0.83-1.56)
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